Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis

Liver International

Volumn 35, Issue 11, 2015, Pages 2425-2432

  Giannone, Ferdinando A ^a,b   Domenicali, Marco ^a,b   Baldassarre, Maurizio ^a,b   Bartoletti, Michele ^a   Naldi, Marina ^a,b   Laggetta, Maristella ^a,b   Bertucci, Carlo ^a   Colecchia, Antonio ^a   Viale, Pierluigi ^a   Bernardi, Mauro ^a,b   Caraceni, Paolo ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Albumin non oncotic properties; Bacterial infection; Cirrhosis; Ischaemia modified albumin

Indexed keywords

C REACTIVE PROTEIN; COBALT; ENDOTOXIN; HUMAN SERUM ALBUMIN; ISCHEMIA MODIFIED ALBUMIN; SERUM ALBUMIN; BIOLOGICAL MARKER; ISCHEMIA-MODIFIED ALBUMIN; ISOPROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BINDING ASSAY; CHEMICAL STRUCTURE; CHOLECYSTITIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; DIVERTICULITIS; ENDOTOXEMIA; ENTERITIS; FEMALE; HEPATIC ENCEPHALOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIA MODIFIED ALBUMIN TO ALBUMIN RATION; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; METABOLIC RATIO; MIDDLE AGED; MOLECULAR BIOLOGY; NONHUMAN; PNEUMONIA; PROGNOSIS; PROGNOSTIC ASSESSMENT; RAT; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; URINARY TRACT INFECTION; ACUTE ON CHRONIC LIVER FAILURE; AGED; ANIMAL; BACTERIAL INFECTIONS; BLOOD; CASE CONTROL STUDY; COMPLICATION; MORTALITY; WISTAR RAT;

ACUTE-ON-CHRONIC LIVER FAILURE; AGED; ANIMALS; BACTERIAL INFECTIONS; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RATS; RATS, WISTAR; ROC CURVE; SERUM ALBUMIN;

EID: 84945451054     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12860     Document Type: Article

References (32)

1. Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013; 58: 1836-46.
2. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16(Suppl 5): 6-11.
3. Anraku M, Chuang VTG, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta 2013; 1830: 5465-72.
4. Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside. Mol Aspects Med 2012; 33: 209-90.
5. Domenicali M, Baldassarre M, Giannone FA, et al. Post-Transcriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014; 60: 1851-60.
6. Stauber RE, Spindelboeck W, Haas J, et al. Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure. Ther Apher Dial 2014; 18: 74-8.
7. Oettl K, Birner-Gruenberger R, Spindelboeck W, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 2013; 59: 978-83.
8. Oettl K, Stadlbauer V, Petter F, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008; 1782: 469-73.
9. Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-64.
10. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42-7.
11. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29-34.
12. Abboud H, Labreuche J, Meseguer E, et al. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23: 216-20.
13. Gunduz A, Turedi S, Mentese A, et al. Ischemia-modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study. Am J Emerg Med 2008; 26: 202-5.
14. Ma S, Jin Y, Xu W, et al. Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis. Endocrine 2012; 42: 570-6.
15. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006; 47: 493-502.
16. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22(Suppl 2): 5-13.
17. Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004; 24: 437-45.
18. Naldi M, Giannone FA, Baldassarre M, et al. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom 2013; 19: 54-9.
19. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
20. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
22. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37, 1437.e1-9.
23. aFerenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
24. Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-5.
25. Jiménez W, Clária J, Arroyo V, Rodés J. Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 1992; 7: 90-7.
26. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60: 1310-24.
27. Erdem SS, Yerlikaya FH, Çiçekler H, Gül M. Association between ischemia-modified albumin, homocysteine, vitamin B(12) and folic acid in patients with severe sepsis. Clin Chem Lab Med 2012; 50: 1417-21.
28. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311-5.
29. Dekker MS, Mosterd A, van 't Hof AWJ, Hoes AW. Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart 2010; 96: 1001-10.
30. Ramasamy I. Biochemical markers in acute coronary syndrome. Clin Chim Acta 2011; 412: 1279-96.
31. Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 2010; 23: 335-40.
32. Kiyici A, Mehmetoğlu I, Karaoğlan H, et al. Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels? J Clin Lab Anal 2010; 24: 273-7.